EGFR and neoplasm: Besides mAbs directed against tumor-associated antigens (e.g., CD20, EGFR, HER-2), innovative molecules, such as bi- or tri-specific antibodies or other NK cell engagers (NKCE), have been recently designed (33, 52–56).